Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Novel calpain inhibitor SNJ-1757 identified as anticataract agent with good corneal permeability

Dec. 23, 2003

Enrollment goal reached for phase III Xibrom trial

Dec. 22, 2003

Oxigene expands ophthalmology R&D program

Dec. 17, 2003

Inhibition of factor 5A1 reduces apoptosis caused by TNF-alpha

Dec. 16, 2003

National Eye Institute supports Genvec PEDF work through SBIR grants

Dec. 15, 2003

Allergan and Inspire sign copromotion agreement for Elestat

Dec. 11, 2003

Clinical trials confirm the good safety profile of anecorvate acetate

Dec. 3, 2003

New calpain inhibitors, their preparation and use, reported by Senju team

Nov. 26, 2003

DES may facilitate repair of damaged nerve cells

Nov. 19, 2003

Two phase III studies for Retaane planned for January

Nov. 18, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...